

**Starting Clinical Trials: The 70- day benchmark**  
**1<sup>st</sup> January 2015 – 31<sup>st</sup> April 2015**

REC Reference	Trial	Date of valid document set receipt	Date of NHS Permission	Date of first recruit	Total Days taken	Reasons for not achieving the 70 day benchmark
13/NE/0344	Study into efficacy and safety of ertugliflozin monotherapy (MK-8835/PF-04971729)	16/04/2014	23/04/2014	05/11/2014	203	Issues surrounding the supply of the IMP from the sponsor. Low recruiting study. 3 Patients consented and progressed to the washout period. Inclusion criteria then re-addressed, 2 have failed this. Only classed as a recruit once randomised after the washout period.
13/EM/0118	ELFIN	22/04/2014	09/05/2014	N/A		Continuing care site only.
13/WM/0202	DRN 819 Leucopatch in diabetic foot ulcers	25/04/2014	12/05/2014	09/07/2014	75	Study not open to recruitment until the 12/06/2014 as waiting for activation from the sponsor.
12/LO/1168	R2W - Subcutaneous Bortezomib, Cyclophosphamide & Ritiximab BCR vs FCR of Walderstrom	12/06/2014	12/06/2014	30/07/2014	48	
13/WM/0419	Mammo 50	14/07/2014	15/07/2014	29/08/2014	46	
13/WA/0184	AML-19	13/08/2014	08/09/2014			Sponsor Delay: Issues with trial centre not having the drug supply/ contract in place nationally.
13/NS/0143	The SIMS Trial	04/09/2014	17/09/2014	05/12/2014	92	Sponsor Delay: Delay in CI completing learning curve in theatres with PI and then PI on annual leave cause delay. Site physically opened to recruitment 03/11/2014.
14/SC/1014	The JANUS 1 Study Incyte INCB 18424362	19/09/2014	10/10/2014	10/03/2015	173	Study not open to recruitment, awaiting sponsors approval on the test images before our site can be activated. Rare disease.
13/SC/0379	RESPIRE (CARD 3360)	22/09/2014	15/10/2014	19/03/2015	178	Study not open to recruitment, elective pacing's temporarily suspended between December 2014 to March 2015.

REC Reference	Trial	Date of valid document set receipt	Date of NHS Permission	Date of first recruit	Total Days taken	Reasons for not achieving the 70 day benchmark
14/EM/1005	CCRN 3204- Phase 3 Masitinib /Placebo + Docetaxel in Metastatic Prostate Cancer V1 AB12003	25/09/2014	15/10/2014	10/03/2015	166	Study not open to recruitment, awaiting IMP from sponsor.
14/WM/0166	Assessing QbTest Utility in ADHD: A Randomised Controlled Trial	26/09/2014	16/10/2014	18/11/2014	53	
11/WM/0287	DESKTOP III - A randomized multicentre study to compare the efficacy of additional tumour debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer	02/10/2014	23/10/2014	17/02/2015	138	Sponsor Delay: Letter received from the trial centre stating our site numbers and that we are open for recruitment from 11/11/2014.
14/YH0085	FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab	13/11/2014	20/11/2014			Pharmacy green light 22/12/2014 study now open to recruitment
13/WA/0205	AML-18	08/01/2015	12/01/2015			Lincoln site open to recruit 13/03/15. Pilgrim site still awaiting confirmation.
12/WM/0187	ROCSS Reinforcement of closure of stoma site	26/01/2015	05/02/2015	06/03/2015	39	
13/SC/0111	FOCUS4: Molecular selection of therapy in colorectal cancer	06/02/2015	25/02/2015			Awaiting Site Initiation.
12/NE/0401	Folic Acid Clinical Trial (FACT)	23/02/2015	09/03/2015			Awaiting Site Initiation.
14/LO/2011	CCRN 2833 DUAL antithrombotic therapy with dabigatran etexilate (RE-DUAL PCI)	13/03/2015	18/03/2015			
14/EM/1130	An Investigation of biomarkers in ACL patients and healthy controls	22/09/2014	24/10/2014			